AI evolves beyond mere algorithms to open up new frontiers in generative AI and agentic AI, and the art of the possible is ...

Element has responded to the lawsuit with a statement saying, “Element is proud of its strong history of innovation. We are ...

Prime Medicine is eliminating 25% of its workforce in a restructuring that includes the company pivoting its prime editing-based pipeline focus to liver disease and programs funded by external ...

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.

Artificial intelligence is changing the skills needed to succeed. A digitally-literate workforce is absolutely critical.

This is the first gene editor to use a CRISPR-associated transposase to make targeted edits at therapeutically useful levels in humans.

10x Genomics has settled patent infringement lawsuits with a pair of rivals, Bruker and Vizgen, through settlements that could reshape competition within the emerging single-cell and spatial genomics ...

BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.

Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows ...

Scientists say study findings indicate that TC IV cells may represent a therapeutic target for the treatment of ...

Estrogen-related receptors (ERRs) regulate muscle mitochondria in mice, revealing a new potential drug targets for metabolic ...

How malaria parasites exploit mechanism for escaping elimination could provide novel strategies targeting chronic malaria ...